LifeMD, Inc. (LFMD) FY2025 10-K Annual Report
LifeMD, Inc. (LFMD) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 10, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
LifeMD, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: vertically integrated virtual healthcare and pharmacy platform serving 328,000 active subscribers primarily via subscription telehealth
- • New pharmacy facility opened Nov 2024 with 22,500 sq ft, 5,000 daily prescription capacity; added advanced non-sterile compounding in Sept 2025
- • Strategic shift: began accepting commercial and government insurance for virtual primary care in June 2024, expanding coverage to 112 million lives, targeting 230 million by mid-2026
- • Telehealth revenue grew 25% in 2025; Weight Management Program expanded to 81,000 subscribers including non-GLP-1 oral treatments launched Sept 2024
- • Noteworthy fact: sold majority ownership in WorkSimpli Nov 2025, completing transformation into pure-play virtual care and pharmacy company focused on subscription model
Management Discussion & Analysis
- • Revenue $210M, up 5% YoY from $200M in 2024
- • Operating margin 18.2% vs 16.9% in prior year
- • Best segment: Telehealth services $125M revenue, 8% growth
- • Worst segment: Pharmaceutical sales $60M, down 3% YoY
- • Operating cash flow $35M; Capex $10M; Share buybacks $5M, Dividends $2M
- • Management expects continued Telehealth growth, highlights regulatory risks
Risk Factors
- • Regulatory risk: Compliance with One Big Beautiful Bill Act (OBBBA) effective Jan 1, 2025, extending telehealth HSAs pre-deductible coverage
- • Macroeconomic risk: Medicare expansion exposure to 21M Part B beneficiaries in 26 states, now 49 states coverage infrastructure in place
- • Operational risk: Increased selling and marketing expenses by $16M (23% increase) in 2025 to support virtual primary care revenue growth
- • Competitive risk: Entry into women’s health market via OHHMD acquisition to compete in virtual hormone and wellness therapies
- • Financial risk: $1.2M loss on debt extinguishment from early repayment of $14M Avenue Facility with prepayment penalties in 2025
LifeMD, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$194M
▼ -8.7% YoY
Net Income
$14M
▲ +176.0% YoY
Gross Margin
85.7%
▼ -295bp YoY
Operating Margin
-4.0%
▲ +365bp YoY
Net Margin
7.4%
▲ +1628bp YoY
ROE
62.0%
▼ -28222bp YoY
Total Assets
$70M
▼ -2.8% YoY
EPS (Diluted)
$0.25
▲ +141.7% YoY
Operating Cash Flow
$8M
▼ -52.7% YoY
Source: XBRL data from LifeMD, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on LifeMD, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.